Evonik expands lipid-based drug delivery capabilities with new GMP manufacturing facility in Vancouver

Positive

AI Analysis

Summary

Evonik is expanding its lipid nanoparticle manufacturing capabilities by opening a new GMP facility in Vancouver with an investment of over 150 million CAD, supported by up to 68 million CAD in external funding, to meet growing demand for LNP development and clinical drug product manufacturing.

Importance:5/10

Sentiment:

0.60

manufacturinglipid nanoparticlesLNPGMP facilitycapacity expansiondrug delivery

Read the original article

Published by PR Newswire Pharma on August 28, 2026 7:00 AM

Read Original